Boundless Bio, Inc. Common Stock (BOLD) - Total Liabilities
Based on the latest financial reports, Boundless Bio, Inc. Common Stock (BOLD) has total liabilities worth $58.55 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Boundless Bio, Inc. Common Stock - Total Liabilities Trend (2016–2024)
This chart illustrates how Boundless Bio, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. See BOLD working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Boundless Bio, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Boundless Bio, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dexter Co Ltd
KQ:206560
|
Korea | ₩67.64 Billion |
|
Grande Group Limited Class A Ordinary Shares
NASDAQ:GRAN
|
USA | $327.05K |
|
Mohenz.Co.Ltd
KQ:006920
|
Korea | ₩19.16 Billion |
|
EMB Mission Bound AB (publ)
ST:NAVIGO-STAM
|
USA | Skr376.93 Million |
|
Pamapol S.A.
WAR:PMP
|
Poland | zł500.62 Million |
|
Taegu Broadcasting Corporation
KQ:033830
|
Korea | ₩6.35 Billion |
|
Ovaro Kiinteistosijoitus Oyj
HE:OVARO
|
Finland | €32.18 Million |
|
Eupe Corporation Bhd
KLSE:6815
|
Malaysia | RM374.69 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Boundless Bio, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Boundless Bio, Inc. Common Stock worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Boundless Bio, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Boundless Bio, Inc. Common Stock (2016–2024)
The table below shows the annual total liabilities of Boundless Bio, Inc. Common Stock from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $55.77 Million | -78.30% |
| 2023-12-31 | $256.98 Million | +62.10% |
| 2022-12-31 | $158.53 Million | +4.36% |
| 2021-12-31 | $151.91 Million | +409.74% |
| 2018-12-31 | $29.80 Million | +35.07% |
| 2017-12-31 | $22.06 Million | -2.74% |
| 2016-12-31 | $22.69 Million | -- |
About Boundless Bio, Inc. Common Stock
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene ampli… Read more